Cargando…
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
BACKGROUND: The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma. METHODS: A Markov decision model was established to carry out the cost‐effectiveness analysis. Three discrete health st...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402838/ https://www.ncbi.nlm.nih.gov/pubmed/32489014 http://dx.doi.org/10.1002/cam4.3121 |